Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgments

Beatrice Chiang (Amgen Inc.) provided medical writing assistance funded by Amgen Inc. and Ben Scott (Scott Medical Communications, LLC) provided editorial assistance funded by Amgen Inc. Bob Dawson (Cactus Communications, on behalf of Amgen Inc.) provided graphics support.

Disclosure statement

A.V. has received honoraria from and has served as a consultant/advisor for Roche, Bristol-Myers Squibb, Amgen Inc., Kite/Gilead, and Pfizer; and has received travel expenses from Roche, Celgene, Bristol-Myers Squibb, AbbVie, and Kite/Gilead. G.H. has served as a consultant/advisor for Roche, Janssen, Celgene, Gilead, Servier, and AbbVie; has received research funding from Roche, Servier, and Celgene; and has received travel expenses from Celgene, Roche, and Janssen. R.C.B. has received honoraria, has served as a consultant/advisor, and has received travel expenses from Amgen Inc., Cellex, GEMoaB, Genmab, Molecular Partners, and Novartis; and is a patent holder for blinatumomab and royalty payments. N.J.M. has received honoraria from Amgen Inc. and Janssen; has served as a consultant/advisor for Amgen Inc. and Roche; and has served on the speakers’ bureau for Amgen Inc. G.G. has served as a consultant/advisor for Autolus Ltd; and has received travel expenses from Roche, Takeda, and Gilead. M-E.G. has received honoraria from Novartis, Roche, Bristol-Myers Squibb, and Janssen-Cilag; and has served as a consultant/advisor for GEMoaB, Roche, and Novartis. K.I., A.Z., and J.F. are employees of and have stock ownership in Amgen Inc. D.C. was an employee of Amgen Inc. at the time of the study and has continued stock ownership in Amgen Inc. L.C. has received honoraria and travel expenses from Amgen Inc.

Data availability statement

Qualified researchers may request data from Amgen clinical trials. Complete details are available at http://www.amgen.com/datasharing.

Additional information

Funding

This study was funded by Amgen Inc.